MetaCap

Veraxa Biotech (VRXA) vs Zentalis Pharmaceuticals (ZNTL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zentalis Pharmaceuticals (ZNTL) has outperformed Veraxa Biotech (VRXA) over the past year, gaining 1.5% versus a loss of 90.1%. Veraxa Biotech is the larger company by market cap ($147.1 million vs $133.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

VRXA-90.10%ZNTL+1.49%
+417%+151%-115%
Nov 21, 20251 yearNov 20, 2026
VRXA-89.58%ZNTL-59.64%
+110%+5%-100%
Sep 30, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

VRXA versus ZNTL key metrics
MetricVRXAZNTL
Share price$1.04$1.36
Market cap$147.06M$133.64M
1-day change+0.97%0.00%
YTD return-90.25%+0.74%
1-year return-90.10%+1.49%
5-year return—-98.21%
EPS (TTM)$-0.57$-1.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)—$-137.06M
52-week high$27.36$6.95
52-week low$0.90$1.30
Distance from 52-week high-96.20%-80.43%
Analyst consensus—strong_buy
Avg. price target upside—+447.06%
Average volume267.82K1.26M
Shares outstanding141.41M98.27M
Employees—106
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZNTL has outperformed VRXA by 91.6 percentage points over the past year.

About Veraxa Biotech

VRXA stock →

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.

Health Care · Biotechnology: Pharmaceutical Preparations

About Zentalis Pharmaceuticals

ZNTL stock →

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

VRXA vs ZNTL FAQ

Which is bigger, Veraxa Biotech or Zentalis Pharmaceuticals?

Veraxa Biotech (VRXA) is larger, with a market capitalization of $147.06M compared with $133.64M for Zentalis Pharmaceuticals (ZNTL).

Which stock has performed better over the past year, VRXA or ZNTL?

ZNTL returned +1.49% over the past 12 months, compared with -90.10% for VRXA (price return, excluding dividends). Past performance does not predict future results.

Are Veraxa Biotech and Zentalis Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons